GDC-0134

• Description :

  GDC-0134 is a potent, selective, orally active, brain-penetrant dual leucine zipper kinase (DLK) inhibitor. GDC-0134 blocks DLK activity in cellular assays and in animal models of neuronal injury. GDC-0134 can be used for the study of amyotrophic lateral sclerosis (ALS) [1].

• UNSPSC :

  12352005

• Target :

  JNK

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/gdc-0134.html

• Purity :

  99.18

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  NC1=C(C=C(C=N1)C2=NC(N3CC(F)(CC3)F)=NC(N4C[C@H]5OC[C@@H]4C5)=C2)OC(F)F

• Molecular Formula :

  C19H20F4N6O2

• Molecular Weight :

  440.39

• References & Citations :

  [1]Jonathan S Katz, et al. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neurol. 2022 Jan;9 (1) :50-66.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1637394-01-4]